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Figure 1: (a) M512 array, (b) M512 dosimetry acquisition of 
1x1cm2 field, (c) Passive M512 MR imaged at 3T, blue circles 
indicate fiducials (d) MR image of water phantom imaged 
without dosimeter noise suppression, (e) MR image of water 
phantom imaged with dosimeter noise suppression. 
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Purpose: There is an important need to improve the 
effectiveness of radio-chemotherapy (RTCT) for cervical 
cancer. These tumors recruit myeloid cells from the bone 
marrow via the CXCL12/CXCR4 pathway, which in turn 
influence vascular function and radiotherapy response. The 
objective of this study was to explore combined treatment 
with Plerixafor (a CXCL12/CXCR4 inhibitor) and standard 
RTCT on primary tumor control and the development of 
metastases, using orthotopic primary xenografts derived 
directly from patients with cervical cancer. 
Materials/Methods: Two primary cervix xenografts (OCICx13 
and OCICx20) were grown in the cervices of immune deficient 
mice.  These tumor models have been shown to mirror the 
clinical and biological behavior of cervical cancer in patients. 
To simulate clinical treatment, image-guided radiotherapy 
(30 Gy in 15 daily fractions) and concurrent weekly cisplatin 
(4 mg/kg) were administered, with or without Plerixafor (5 
mg/kg/day). The primary endpoints were tumor growth 
delay, the frequency of lymph node metastases and animal 
survival. Chemokine expression and neutrophil recruitment 
were evaluated by immunohistochemistry. Acute gut toxicity 
was assessed using the crypt cell assay. Blood and normal 
organs were examined for late toxicity. 
Results: The combination of RTCT and Plerixafor produced 
substantial tumor growth delay, reduced metastases and 
improved survival compared to standard RTCT alone in 
patient-derived xenograft models. There was a reduction in 
chemokine signaling (CXCL12/CXCR4) and myeloid cell 
infiltration (GCSF, CD11b) with combination treatment 
compared to RTCT alone. There was no effect of Plerixafor 
on acute GI toxicity, nor were there changes in blood counts 
or organ morphology to indicate increased late hematological 
or normal tissue toxicity.  
Conclusion: This preclinical study demonstrates that the 
addition of Plerixafor to standard RTCT for cervical cancer 
improves local tumor control and reduced metastases with no 
increase in toxicity. Plerixafor is commercially available for 
other indications, which will facilitate translation of these 
findings to phase I/II clinical studies. 
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Curative 3D standard external beam radiotherapy (EBRT) for 
prostate cancer has been able to improve disease control 
with dose escalation during the last 15 years though against 
the token of significant toxicity. Exploring changes in 
fractionation, doses-distribution optimization with modulated 
RT, and reducing CTV-PTV safety margins due to off- or on-
line imaging before or during irradiation, may be alternatives 
worth to be implemented in order to reach the highest 
possible toxicity-free cure rates. 
Accurate imaging helping to better define the irradiation 
target/s (e.g., multiparametric MRI, PET-CT/MRI, SPECT); 
modulated EBRT optimizing the dose distribution; and image 
guided RT (e.g., kV imaging, CBCT, fiducial markers, 
transponders, endorectal balloons, recto-prostatic spacers) 
controlling for patient repositioning and organ motion are 
presently available allowing the implementation of high 
precision treatment techniques.  
Biomathematical modeling has helped to better understand 
the very special dose-response relationships of EBRT on 
prostate cancer concerning fractionation sensitivity (low α/β 
value), overall treatment time (tumor cell repopulation 
kinetics), and fraction delivery time (potential biological 
effective dose modifier). All these factors are rather 
suggestive that prostate cancer patients, especially those 
with low- or intermediate-risk disease, can be better treated 
with “more” dose/fraction, “less” number of fractions, and a 
“shorter” time protraction and delivery time per fraction. 
Two opposed modalities conceived to deliver large doses in 
few fractions are either stereotactic body RT (SBRT) or high-
dose rate brachytherapy (HDR-BT) given alone or as a boost. 
The latter procedure may be limited by dose inhomogeneities 
and geographical misses. Even a small underdosage of the 
target or a heterogeneous dose-rate delivery may have a 
negative influence on outcome. This seems to be especially 
determinant for tumors with very low α/β values as it is the 
case for prostate cancer. Thus, SBRT may be theoretically 
more advantageous because the radiobiological reliability of 
a homogeneous dose distribution compared to HDR-BT, 
besides being less invasive and probably less costly.  
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Proton radiotherapy provides a promising and emerging 
treatment approach for cancer patients. However, 
understanding of the differences in terms of DNA damage and 
cell proliferation post-proton irradiation is relatively poor. 
The purpose of this study was to evaluate DNA damage 
induced by proton beams using various cytogenetic and 
molecular methods. 
ICTR-PHE 2016  S75 
 
The response of human peripheral blood lymphocytes (HPBL) 
was characterized using: the cytokinesis-blocked 
micronucleus (CBMN) assay, premature chromosome 
condensation (PCC) assay, FITC-Annexin V labeling 
procedure, chip-based DNA ladder assay, and the comet 
assay. The samples of whole blood or isolated lymphocytes 
collected from 10 different healthy donors were irradiated in 
vitro with 60 MeV protons or 250 kV X-rays, in the dose range 
of 0.3 Gy – 4.0 Gy. The HPBL were located in Eppendorf 
vessels located in especially prepared PMMA (Poly(methyl 
methacrylate)) phantom and irradiated with protons in the 
fully modulated Spread Out Bragg Peak (SOBP) mode. 
Dosimetry was performed in accordance to the 
recommendations of the IAEA TRS-398 protocol. 
Peripheral blood lymphocytes showed decreased ability to 
proliferate after irradiation that reduced with increasing 
radiation doses of either radiation types as evident by the 
reduced nuclear division index seen in the cytokinesis-block 
micronucleus (CBMN) assay. Proton irradiation resulted in a 
relatively higher incidence of cell death compared to those 
irradiated with X-rays. Cell death was due to both apoptosis 
and necrosis. Chip-based DNA ladder assay showed different 
degrees of fragmentation of the genomic DNA after proton 
irradiation indicating peripheral blood lymphocytes, which 
are prone to undergo an apoptotic mode of cell death, 
predominantly undergo a necrotic mode of cell death after 
proton irradiation. Differences in DNA damages following 
irradiation with protons and X-rays were apparent also at the 
intracellular distribution of cytogenetic damages as 
visualized by the PCC and CBMN assays. Alkaline comet assay 
showed a linear dose-response relationship for the DNA 
damage immediately after irradiation. Dose response 
relationship for the DNA damage indicated higher efficiency 
of protons in inducing DNA strand breaks presented as the 
ratio of the two α coefficients (1.37).   
Our results, contribute to a better understanding of the 
differences in the response of human peripheral blood 
lymphocytes to proton and X-ray irradiation. These studies 
may eventually help determine the suitability of patients 
with cancer for treatment with a given radiation type based 
on their normal tissue response and ability to predict 
treatment related adverse effects.    
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In the clinical practice of proton therapy, the biologic 
effectiveness of protons relative to photons (i.e., the 
"relative biologic effectiveness" or RBE) has simplistically 
been assumed to have a generic fixed value of 1.1.  This 
value is based on an average of results of numerous in-vitro 
and in-vivo experiments conducted under limited conditions – 
most commonly, at high doses per fraction (e.g., 6–8 Gy) and 
in the middle of the spread-out Bragg peak where the RBE is 
relatively constant and close to the average value of 1.1.  
Furthermore, the RBE data have been acquired for only a 
limited number of cell lines, tissues, and endpoints.  To 
justify the assumption of RBE of 1.1, it is argued that, 
clinically, no adverse responses have been reported with its 
use.  However, large uncertainties in the treatment 
processes may have obscured the variability of the RBE. 
In reality, the RBE is a function of multiple variables 
including dose per fraction, linear energy transfer (LET), cell 
and tissue type, endpoint, etc. It has been shown to vary 
from values lower than 1.1, perhaps lower than even 1, to as 
much as 4.  Emerging clinical evidence, still somewhat 
anecdotal, is showing that neglecting RBE variability may 
lead to unforeseen toxicities and recurrences.  However, 
establishing an unequivocal connection between unforeseen 
events and the use of RBE of 1.1 is challenging since there 
are numerous confounding factors.   These include 
uncertainty in the particle therapy dose actually delivered 
and patient-specific factors. 
As a consequence, there is a continuing debate about the 
validity of the assumption of RBE=1.1.  At the same time, 
efforts to obtain more precise and accurate RBE information 
are accelerating.  High-precision in-vitro and in-vivo 
experiments are being designed and conducted to obtain the 
large amounts of data required.  Attempts are also being 
made to extract clinically-relevant RBE from treatment 
response data, particularly from PET and MR image 
biomarkers.  Such RBE data need to be incorporated into 
predictive models of RBE, which can be used to explain 
treatment response more reliably and to design treatment 
plans.  The improved knowledge of variable RBE is expected 
to not only help explain unforeseen events but, more 
importantly, to lead to improvements in treatment planning, 
which in turn may enhance the effectiveness of proton 
therapy.  This could, for instance, be achieved by 
incorporating variable RBE in the optimization of IMPT in such 
a way as to confine high RBE protons to within the target 
volume and away from critical normal tissues. 
This presentation will focus on proton therapy.  For particles 
heavier than protons, the RBE is generally not assumed to 
have a fixed generic value.  Nevertheless, considerable 
uncertainties exist in RBE for all particles, which can have a 
significant impact on outcomes.  
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Most of adult stem cells are maintained in a quiescent state 
considered as a survival mechanism responding to DNA 
damages induced by ionizing radiation. Stem cells then are 
able to rapidly proliferate and are essential for restoration of 
tissue function. In the brain, Neural Stem Cells (NSCs) are 
known to be responsible for adult neurogenesis participating 
to cognition and Whole Brain Radiotherapy (WBRT) induces 
memory loss due to impaired neurogenesis. Here we 
compared the effect of FLASH versus conventional-RT on 
NSCs after WBRT and especially investigated quiescence and 
neurogenesis potential.  
WBRT at FLASH and conventional dose rate was performed 
using LINAC prototypes. Mice received single doses RT at 
50GyFLASH (>50Gy/s), 10GyCONV (0.04Gy/s) and sham-RT. 
Two months post-IR, before the sacrifice, cognitive tests 
were performed to evaluate memorization impairments. Two 
hours before the sacrifice animals received BrdU injection. 
Brains were collected for immunohistochemical analysis of 
NSCs quiescence using FoxO3-Sox2 (Renault et al. 2009). 
We showed that 50GyFLASH-RT does not induce any 
macroscopic toxicity whereas 10GyCONV is the maximum 
tolerated dose (Acharya et al. 2009). We observed a 
memorization loss after 10GyCONV-RT whereas cognition is 
not affected at 50GyFLASH two months post-IR. At the same 
time point, SGZ BrdU+ clusters are maintained at doses up to 
20GyFLASH whereas 10GyCONV totally impairs the 
